1-20 of 821
Guillermo Garcia-Manero, MD
Close
Sort by
Journal Articles

Clinical Outcomes with Hypomethylating Agents in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T); A Case Series

Maria Tariq Siddiqui, MD, Rashmi Kanagal-Shamanna, MD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Lucia Masarova, MD, Elias Jabbour, MD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Naval Daver, MD, Gautam Borthakur, MD, Sherry A. Pierce, BSN, BA, Srdan Verstovsek, MD PhD, Prithviraj Bose, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban-Bravo, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-142084
Published: 2020
Journal Articles

Initial Results of a Phase 1 Dose Escalation Study of CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) after Failure to Hypomethylating Agents

Guillermo Montalban Bravo, MD, Elias Jabbour, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Zeev E. Estrov, MD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Kelly S. Chien, MD, Graciela M. Nogueras González, MPH, Xiao Qin Dong, Stefan Faderl, MD, Heather Schneider, BSN, RN, Rosmy B. John, MSN, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–3.
https://doi.org/10.1182/blood-2020-139942
Published: 2020
Journal Articles

Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories

Jorge M. Ramos Perez, Veronica A Guerra, MD, Danielle Hammond, MD, Kelly S. Chien, MD, Rashmi Kanagal-Shamanna, MD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Shilpa Paul, PharmD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Naval Daver, MD, Farhad Ravandi, MBBS, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Koichi Takahashi, MD PhD, Zeev E. Estrov, MD, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban-Bravo, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
https://doi.org/10.1182/blood-2020-142469
Published: 2020
Journal Articles

Phase II Study of Venetoclax Added to Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Demonstrates High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) and Excellent Tolerability in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Tapan M. Kadia, MD, Gautam Borthakur, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Koji Sasaki, MD, Ghayas C. Issa, MD, Maro Ohanian, DO, Guillermo Montalban Bravo, MD, Nicholas J. Short, MD, Nitin Jain, MD, Alessandra Ferrajoli, MD, Kapil N. Bhalla, MD, Elias Jabbour, MD, Rashmi Kanagal-Shamanna, MD, Koichi Takahashi, MD PhD, Rashmi Malla, RN, BSN, Kelly Marek, Mark Brandt, BS, Uday R. Popat, MD, Michael Andreeff, MD PhD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 17–19.
https://doi.org/10.1182/blood-2020-142092
Published: 2020
Journal Articles

Prognostic and Therapeutic Implications of Mutant TP53 Variant Allelic Frequency in Adults with Newly Diagnosed TP53 -Mutated Acute Myeloid Leukemia

Nicholas J. Short, MD, Guillermo Montalban-Bravo, MD, Hyunsoo Hwang, Jing Ning, PhD, Miguel Franquiz, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Courtney D. Dinardo, MDMSc, Farhad Ravandi, MBBS, Guillermo Garcia-Manero, MD, Koichi Takahashi, MD PhD, Marina Konopleva, MD PhD, Naval Daver, MD, Elias Jabbour, MD, Musa Yilmaz, MD, Ghayas C. Issa, MD, Michael Andreeff, MD PhD, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 33–34.
https://doi.org/10.1182/blood-2020-134312
Published: 2020
Journal Articles

Interim Analysis of the Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML

Curtis Lachowiez, MD, Marina Konopleva, MD PhD, Tapan M. Kadia, MD, Naval Daver, MD, Sanam Loghavi, MD, Sa A Wang, MD, Maria Adeoti, R.N., Sherry A. Pierce, BSN, BA, Koichi Takahashi, MD PhD, Nicholas J. Short, MD, Koji Sasaki, MD, Gautam Borthakur, MD, Ghayas C. Issa, MD, William G. Wierda, MD PhD, Naveen Pemmaraju, MD, Guillermo Montalban Bravo, MD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Lucia Masarova, MD, Musa Yilmaz, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Steven M. Kornblau, MD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD, Courtney D. Dinardo, MDMSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–20.
https://doi.org/10.1182/blood-2020-134300
Published: 2020
Journal Articles

Prognostic Significance of Genetic Alterations in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated with Hyper-CVAD Plus Dasatinib or Hyper-CVAD Plus Ponatinib

Yuya Sasaki, MDPhD, Hagop M. Kantarjian, MD, Nicholas J. Short, MD, Nitin Jain, MD, Koji Sasaki, MD, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Guillermo Garcia-Manero, MD, Latasha Little, BS, Curtis Gumbs, Li Zhao, PhD, P Andrew Futreal, PhD, Feng Wang, PhD, Ken Furudate, DDM, PhD, Rebecca Garris, MSc, Koichi Takahashi, MD PhD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-136676
Published: 2020
Journal Articles

Quizartinib with Decitabine +/- Venetoclax Is Highly Active in Patients (Pts) with FLT3 -ITD Mutated (mut) Acute Myeloid Leukemia (AML): Clinical Report and Signaling Cytof Profiling from a Phase IB/II Trial

Musa Yilmaz, MD, Hagop M. Kantarjian, MD, Muharrem Muftuoglu, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Gautam Borthakur, MD, Courtney D. DiNardo, MD MSCE, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Yesid Alvarado, MD, Guillermo Montalban Bravo, MD, Carissa Jurisprudencia, Allison M. Pike, RN, Maro Ohanian, DO, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Vivian Ruvolo, MS, Farhad Ravandi, MBBS, Michael Andreeff, MD PhD, Naval Daver, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–20.
https://doi.org/10.1182/blood-2020-142687
Published: 2020
Journal Articles

SF3B1 -Mutant Myelodysplastic Syndrome with Ringed Sideroblasts (MDS-RS) at the Single-Cell Level

Rashmi Kanagal-Shamanna, MD, Vera Adema, PhD, Feiyang Ma, Bs, Andrea Santoni, PhD, Hui Yang, MD PhD, Irene Ganan-Gomez, PhD, Natthakan Thongon, PhD, Guillermo Montalban-Bravo, MD, Matteo Pellegrini, PhD, Carlos E. Bueso-Ramos, MD PhD, Guillermo Garcia-Manero, MD, Simona Colla, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–51.
https://doi.org/10.1182/blood-2020-141928
Published: 2020
Journal Articles

Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia

Abhishek Maiti, MBBS, Courtney D. DiNardo, MD MSCE, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Tapan M. Kadia, MD, Naval Daver, MD, Nicholas J. Short, MD, Musa Yilmaz, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Ghayas C. Issa, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Maro Ohanian, DO, Koichi Takahashi, MD PhD, Guillermo Montalban-Bravo, MD, Lucia Masarova, MD, Jan A. Burger, MD PhD, Philip A. Thompson, MB, MS, Srdan Verstovsek, MD PhD, Koji Sasaki, MD, Michael Andreeff, MD PhD, Caitlin R. Rausch, PharmD, Kathryn Montalbano, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD, Farhad Ravandi, MBBS
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–25.
https://doi.org/10.1182/blood-2020-138773
Published: 2020
Journal Articles

Phase II Study of CPX-351 Plus Venetoclax in Patients with Acute Myeloid Leukemia (AML)

Tapan M. Kadia, MD, Gautam Borthakur, MD, Koichi Takahashi, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Naveen Pemmaraju, MD, Elias Jabbour, MD, Nitin Jain, MD, Nicholas J. Short, MD, Wei Qiao, PhD, Lade Adewale, Caitlin R. Rausch, PharmD, Sherry A. Pierce, BSN, BA, Yesid Alvarado, MD, Amin M. Alousi, MD, Uday R. Popat, MD, Issa F. Khouri, MD, Guillermo Garcia-Manero, MD, Marina Konopleva, MD PhD, Jorge E. Cortes, MD, Farhad Ravandi, MBBS, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–22.
https://doi.org/10.1182/blood-2020-142074
Published: 2020
Journal Articles

Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort

Patrick K Reville, MD, Graciela M. Nogueras González, MPH, Farhad Ravandi, MBBS, Koji Sasaki, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Elias Jabbour, MD, Naveen Pemmaraju, MD, Michael Andreeff, MD PhD, Srdan Verstovsek, MD PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Maro Ohanian, DO, Sherry A. Pierce, BSN, BA, Zeev E. Estrov, MD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
https://doi.org/10.1182/blood-2020-141837
Published: 2020
Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Jorge M. Ramos Perez, Tapan M. Kadia, MD, Guillermo Montalban-Bravo, MD, Stefan Faderl, MD, Koji Sasaki, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Lucia Masarova, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Gautham Borthakur, Hind Al Azzawi, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Yesid Alvarado, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–34.
https://doi.org/10.1182/blood-2020-142570
Published: 2020
Journal Articles

Distinct Prognostic Effects of TP53 Mutations in Newly Diagnosed Versus Relapsed/Refractory (R-R) Patients (pts) with B-Acute Lymphoblastic Leukemia (ALL) Treated with Mini-Hcvd-Inotuzumab Ozogamicin with or without Blinatumomab Regimens

Rashmi Kanagal-Shamanna, MD, Hagop M. Kantarjian, MD, Joseph D. Khoury, MD, Koichi Takahashi, MD PhD, Guillermo Montalban-Bravo, MD, Nicholas J. Short, MD, C. Cameron Yin, MD PhD, Keyur Patel, MD PhD, Sanam Loghavi, MD, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Susan M. O'Brien, MD, Rajyalakshmi Luthra, PhD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–43.
https://doi.org/10.1182/blood-2020-142012
Published: 2020
Journal Articles

Outcomes of De Novo Acute Myeloid Leukemia with Monocytic Differentiation (FAB M4/5) Treated with Venetoclax and Decitabine

Abhishek Maiti, MBBS, Sergej Konoplev, MD PhD, Courtney D. DiNardo, MD MSCE, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Naval Daver, MD, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Ghayas C. Issa, MD, Nicholas J. Short, MD, Musa Yilmaz, MD, Yesid Alvarado, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Nitin Jain, MD, Maro Ohanian, DO, Koichi Takahashi, MD PhD, Philip A. Thompson, MB, MS, Caitlin R. Rausch, PharmD, Kathryn Montalbano, Sherry A. Pierce, BSN, BA, Keyur P. Patel, MBBS, PhD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–13.
https://doi.org/10.1182/blood-2020-138580
Published: 2020
Journal Articles

Initial Results of a Phase I/II Study of Venetoclax in Combination with Azacitidine in Treatment-Naive and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Kiyomi Morita, MDPhD, Kiran Naqvi, MD MPH, Guillermo Montalban Bravo, MD, Philip A. Thompson, MB, MS, Koichi Takahashi, MD PhD, Yesid Alvarado, MD, Elias Jabbour, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-140644
Published: 2020
Journal Articles

Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors

Koji Sasaki, MD, Hagop M. Kantarjian, MD, Ghayas C. Issa, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD, William G. Wierda, MD PhD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSCE, Jeffrey Skinner, MHA, Rita Khouri, Naveen Pemmaraju, MD, Patrice Nasnas, MD, Sara E Dellasala, BS, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–44.
https://doi.org/10.1182/blood-2020-143023
Published: 2020
Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia in Lymphoid Blast Crisis (CML-LBC) and Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with Hyper-CVAD and Dasatinib

Kiyomi Morita, MDPhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Koji Sasaki, MD, Nitin Jain, MD, Marina Konopleva, MD PhD, Nicholas J. Short, MD, Koichi Takahashi, MD PhD, Rita Khouri, Patrice Nasnas, MD, Courtney D. DiNardo, MD MSCE, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Guillermo Montalban Bravo, MD, Ghayas C. Issa, MD, Jorge E. Cortes, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–48.
https://doi.org/10.1182/blood-2020-141230
Published: 2020
Journal Articles

Updated Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Previously-Untreated Patients with Higher-Risk Myelodysplastic Syndrome

Kelly S. Chien, MD, Gautam Borthakur, MD, Kiran Naqvi, MD MPH, Naval Daver, MD, Guillermo Montalban Bravo, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MD MSCE, Elias Jabbour, MD, Yesid Alvarado, MD, Michael Andreeff, MD PhD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly A. Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 38–39.
https://doi.org/10.1182/blood-2020-140521
Published: 2020
Journal Articles

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Michael R. Savona, MD, James K. McCloskey, MD, Elizabeth A. Griffiths, MD, Karen W.L. Yee, MD, Aref Al-Kali, MD, Amer M. Zeidan, MBBS, MHS, H. Joachim Deeg, MD, Prapti A. Patel, MD, Mitchell Sabloff, MSc,MDFRCPC, Mary-Margaret Keating, MD FRCPC, Kim-Hien Dao, DO, PhD, Nancy Zhu, MD, Nashat Gabrail, MD, Salman Fazal, MD, Joseph Maly, MD, Olatoyosi Odenike, MD, Hagop M. Kantarjian, MD, Amy E. DeZern, MD, Casey L. O'Connell, MD, Gail J. Roboz, MD, Lambert Busque, MD, Richard A. Wells, MD DPhil, Harshad Amin, MD, Jasleen K. Randhawa, MD, Brian Leber, MD, Yong Hao, MD PhD, Harold N. Keer, MDPhD, Mohammad Azab, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–38.
https://doi.org/10.1182/blood-2020-133855
Published: 2020